-
These 44 crore doses of COVID-19 vaccines will be delivered by their makers between August and December 2021, the Union Health Ministry said.
-
Anvisa also approved a proposal to import Russia’s Sputnik V vaccine.
-
The Companies manufacturing COVID-19 vaccination in India have given only "Emergency Use Authorization for vaccinating people of 18 years age and above
-
US-based Ocugen will make an upfront payment and milestone payment upon first commercial sale in Canada to Bharat Biotech, in addition to sharing the profit from sales of Covaxin in Canada
-
For vaccines to result in actual vaccination of people, highly coordinated efforts are required from international supply chains, manufacturers, regulators and State and Central government agencies, says Bharat Biotech
-
Anvisa recently approved the Covaxin clinical trial in Brazil, which will study the application of two doses, with 28 days of interval, involving 4,500 volunteers
-
Anticipating the shortages, many States including Telangana had recently gone for global tenders
-
Regulatory approvals for Covaxin are in process in more than 60 countries including USA, Brazil and Hungary, says the Hyderabad company.
-
The daily vaccination rate has fallen to 1.3 million doses despite India not exporting the vaccines now
-
Hyderabad: Hyderabad-based Bharat Biotech said it will ramp up the manufacturing capacities for Covaxin, at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech. The company plans to produce 200 million (20 crore) doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based […]
-
Company plans to produce an additional 200 million doses of Covaxin per annum in the GMP facilities located at Ankleshwar, Gujarat, starting from the fourth quarter of 2021
-
The discussions are currently ongoing with Bharat Biotech towards reviewing the infrastructure at Hester, the technology adaption process and the regulatory compliances.
-
The Minister spoke about his personal isolation experience to the decision on imposing lockdown, vaccine for children to India seeking help from other countries, among other things
-
States may face delays in getting approvals from Indian drug regulatory authorities
-
States like Telangana opting for global tenders to procure vaccine is a pragmatic decision, given the Centre's opaque policy
-
The price factor will not have any impact on the ultimate beneficiary namely, the eligible person getting the vaccine since all state governments have already declared their policy decision.
-
To enhance vaccination penetration into corporate hubs and housing societies in Hyderabad, Bengaluru and Chennai
-
"Now, this is something we are still gaining data on, but most recent data looking at convalescent sera of Covid-19 cases in people who received Covaxin, it was found to neutralise the 617 variant," Fauci was quoted as saying during the White House press briefing
-
This message was conveyed to Chief Secretary Somesh Kumar who held a meeting with Dr. Krishna Ella, MD, Bharat Biotech on Tuesday at BRKR Bhavan following directions from Chief Minister K. Chandrashekar Rao.
-
Bharat Biotech CMD Krishna M Ella said the company is supplying the vaccine to the Central Government at Rs 150 per dosage